Lupus & antiphospholipid syndrome
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network
Authors' conclusion
CR and PR rates at week 52 were consistent with the standard-of-care response rates observed in prospective registrational LN trials.
Study context
- Population
- Patients from US academic medical centres with class III, IV and/or V Lupus Nephritis (LN) and baseline urine protein/creatinine (UPCR) ≥ 1.0, receiving standard-of-care therapy (Accelerating Medicines Partnership (AMP) Lupus Network)
- Participants
- 180 patients
- Outcome
- Response to standard-of-care therapy: CR (UPCR < 0.5; normal serum creatinine or ≤ 125% of baseline; prednisone ≤ 10 mg/day) or PR (> 50% reduction in UPCR; normal serum creatinine or ≤ 125% of baseline; prednisone ≤ 15 mg/day)
- Follow-up
- Week 52
Methodological detailslongitudinal, multicentre
- Longitudinal
- Multicentre
Main finding
As reported in the abstract
Response rates to standard of care
Complete response (CR)
22.2%
Partial response (PR)
21.7%
Non-responder (NR)
41.7%
Not determined (ND)
14.4%
Observational data: associations, not effects.
Further findings
Predictors of week 52 CR or PR attainment
| aOR (95% CI) | P value | ||
|---|---|---|---|
| Baseline UPCR > 3 | 3.71 (1.34–10.24) | P = 0.012 | |
| > 25% decrease in UPCR from baseline to week 12 | 2.61 (1.07–6.41) | P = 0.036 | |
| Positive anti-dsDNA antibody | 2.61 (0.93–7.33) | P = 0.069 | |
| 0.050.21520Adjusted odds ratio (log scale) |
| Outcome | aOR (95% CI) | P value | |
|---|---|---|---|
| Predictors of week 52 CR or PR attainmentLower chronicity index · per unit decrease | 1.33 (1.10–1.62) | P = 0.003 | |
| 0.512Adjusted odds ratio (log scale) |
Sustained response
- Week 12 CR sustained through week 52
- 8/180 (4.4%)
- Week 12 PR or CR sustained through week 52
- 18 (10%)
- Sustained PR or CR at weeks 26 and 52
- 47 (26.1%)
Original publication
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis Res Ther. Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →